Showing results (441-450 of 530) with videos related to

Sort By:
Pageof 53
The Lancet. Microbe|January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trialNorbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Contemporary Clinical Trials|March 10, 2025
Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trialPawandeep Kaur, Lelia H Chaisson, Zana Wangari Kiragu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
The New England Journal of Medicine|October 23, 2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosisAmina Jindani, Thomas S Harrison, Andrew J Nunn, et al.
Oecologia|June 25, 2016
Phylogenetic turnover along local environmental gradients in tropical forest communitiesC A Baldeck, S W Kembel, K E Harms, et al.
The European Respiratory Journal|August 3, 2019
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidanceHelen R Stagg, Graham H Bothamley, Jennifer A Davidson, et al.
PLOS Global Public Health|October 24, 2024
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options TrialAllan Musinguzi, Joan R Kasidi, Jillian L Kadota, et al.
Antimicrobial Agents and Chemotherapy|August 23, 2017
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary TuberculosisR E Aarnoutse, G S Kibiki, K Reither, et al.
Pageof 53